Ionis Pharmaceuticals (NASDAQ:IONS) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)
Ionis Pharmaceuticals (IONS): Valuation Insights Following FDA Breakthrough Therapy Status for Olezarsen [Yahoo! Finance]
Ionis Pharmaceuticals (IONS) Up 5.4% After EMA Nod and $700M Raise—Has the Bull Case Changed? [Yahoo! Finance]
Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)